Search
Now showing items 11-11 of 11
Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy
(
Marshfield Clinic
, 2022 , Article)
Objective: Within the last decade, the use of ibrutinib, a first-generation, non-selective, irreversible Burton's tyrosine kinase inhibitor for the treatment of hematological malignancies has proven highly effective in ...